Research & Development
The Game-Changing Influence of Key Opinion Leaders in Healthcare
Evalueserve IP and R&D Drive Innovation with Strategic IP and R&D Solutions Visit Website Introduction Key Opinion Leaders (KOLs) are crucial
Evalueserve IP and R&D Drive Innovation with Strategic IP and R&D Solutions Visit Website Introduction Key Opinion Leaders (KOLs) are crucial
Healthcare is rapidly transforming with digital health, offering benefits like improved patient outcomes, greater efficiency, and cost reduction. However, realising these advantages requires close collaboration between healthcare providers, policymakers, and technology companies. By working together, a cohesive ecosystem can be created that uses technology to deliver patient-centric care.
The Cell and Gene Therapy (CGT) Area has gained traction in recent years. A majority of big pharma has CGT assets in their pipeline. While it has a strong pipeline, the area witnessed a continued flow of investment. In our latest industry report on Cell and Gene Therapy Sector Performance and Outlook, we discuss how and why we believe that the CGT area has a lot to offer and except to see continued growth.
Deal making in the global healthcare industry has been relatively slow in 2022, compared with a blockbuster 2021. Investors were primarily forced to hold off on deal making because of the uncertainty regarding the global growth outlook.
The increased demand on healthcare services will be compounded by the apparent increased risk of infection among healthcare workers.
According to the International Monetary Fund, the recession triggered by the pandemic will likely be “way worse” than the 2008–09 global financial crisis.
The Covid-19 pandemic has exposed glaring fault lines in the medical care infrastructure, and in emergency health response systems around the globe.